Table 2.

Change from Baseline to 6 Months in Clinical and Inflammatory Measures with Imatinib and Placebo.^*

Measure	Change from Baseline		P Value
	Imatinib	Placebo
PEF (liters/min)
Morning	7.3±46.1	−6.4±39.3	0.38
Evening	8.3±53.6	−8.2±37.2	0.31
FeNO (ppb)	7.89±33.0	−5.92±33.2	0.11
Maximum post-bronchodilation FEV1 (liters)	0.01±0.2	−0.08±0.26	0.10
ACQ-6 score	−0.62±0.96	−0.49±0.89	0.31
AQLQ score	0.55±1.0	0.25±0.80	0.11
ASUI score	0.07±0.20	0.05±0.18	0.62
Airway-wall thickness (%)†	−0.0040± 0.03	−0.0027±0.02	0.13
Airway-wall area (%)†	0.0002±0.02	0.0002±0.02	0.25
Peripheral-blood eosinophil count per cubic millimeter	−10.22±50.6	−2.59±25.6	0.94
BAL eosinophils (%)	2.55±8.8	−2.63±10.4	0.15
Tryptase-positive mast-cell count per square millimeter
Total airway	−54.2±96.5	−32.3±79.8	0.11
Airway smooth muscle	−102.7±167.9	−79.2±157.3	0.07
No. of positive skin-prick tests	−0.71±1.62	−0.61±2.4	0.87
BAL tryptase (ng/ml)	−0.74±2.35	0.43±2.19	0.12
BAL prostaglandin D2 (pg/ml)	12.2±57.2	−4.2±54.4	0.33
BAL cysteinyl leukotrienes (pg/ml)	3.0±37.3	6.5±32.9	0.56
BAL histamine (nmol/liter)	2.1±6.3	−1.1±13.4	0.54
Urinary prostaglandin D2 metabolite (ng/mg creatinine)	−0.30±1.5	0.39±1.73	0.18
Urinary leukotriene E4 (ng/mg creatinine)	0.07±0.65	0.01±0.18	0.47

^*Group comparisons were adjusted for baseline values and assessed with the use of the linear model. All patients who underwent randomization were included. Baseline measures are provided in Table S4 in the Supplementary Appendix. On the basis of a Poisson regression model, from baseline to 6 months, a total of 16 asthma exacerbations occurred in the imatinib group and 20 exacerbations occurred in the placebo group (P = 0.36). BAL denotes bronchoalveolar lavage.

^†Measurement was made with the use of three-dimensional multidetector computed tomography.